ACM
BBH icon

Argentus Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Argentus Capital Management’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5
Closed -$1K – 613
2015
Q4 		$1K Hold
5
– – ﹤0.01% 560
2015
Q3 		$1K Buy
+5
New +$662 ﹤0.01% 631

Other funds holding BBH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFM
Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Argentus Capital Management's BBH Position: Q1 2016 in Review

Argentus Capital Management sold out of VanEck Biotech ETF (BBH) in Q1 2016, closing a stake of 5 shares — an estimated $1K sold.

Argentus Capital Management first reported a position in BBH in Q3 2015 and held it in 2 quarters. The position peaked at $1K in Q4 2015. 71 funds tracked by Wall St. Rank hold BBH as of Q1 2016.

  • Argentus Capital Management reported no remaining VanEck Biotech ETF position as of Q1 2016 after selling out during the quarter.
  • Argentus Capital Management sold 5 VanEck Biotech ETF shares in Q1 2016, an estimated $1K.
  • Argentus Capital Management first reported a position in VanEck Biotech ETF in Q3 2015 and held it in 2 quarters.
  • Argentus Capital Management's VanEck Biotech ETF position peaked at $1K in Q4 2015.
  • 71 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2016.

Based on Argentus Capital Management's 13F filing for Q1 2016, filed 13 May 2016.